{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:14Z","timestamp":1786982114923,"version":"build-2736575974"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-024-01265-9","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T18:21:08Z","timestamp":1735496468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Statin therapy in primary and secondary cardiovascular disease prevention"],"prefix":"10.1007","volume":"27","author":[{"given":"Rodis D.","family":"Paparodis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Bantouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarantis","family":"Livadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Angelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"10","key":"1265_CR1","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1111\/bcp.14811","volume":"87","author":"I Daghlas","year":"2021","unstructured":"Daghlas I, Gill D. Low-density lipoprotein cholesterol and lifespan: A Mendelian randomization study. Br J Clin Pharmacol. 2021;87(10):3916\u201324. https:\/\/doi.org\/10.1111\/bcp.14811.","journal-title":"Br J Clin Pharmacol"},{"issue":"25","key":"1265_CR2","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2012.09.017.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1265_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019;321(4):364\u201373. https:\/\/doi.org\/10.1001\/jama.2018.20045.","journal-title":"JAMA"},{"key":"1265_CR4","unstructured":"Michael D. Shapiro D, MCR and Kenneth R. Feingold, MD. Monogenic Disorders Causing Hypobetalipoproteinemia. Endotext; 2024."},{"issue":"4","key":"1265_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","volume":"21","author":"J Luo","year":"2020","unstructured":"Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21(4):225\u201345. https:\/\/doi.org\/10.1038\/s41580-019-0190-7.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"25","key":"1265_CR6","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","journal-title":"Circulation"},{"issue":"1","key":"1265_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"7","key":"1265_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/0002-9149(94)90307-7","volume":"74","author":"RH Bradford","year":"1994","unstructured":"Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74(7):667\u201373. https:\/\/doi.org\/10.1016\/0002-9149(94)90307-7.","journal-title":"Am J Cardiol"},{"issue":"20","key":"1265_CR9","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301\u20137. https:\/\/doi.org\/10.1056\/NEJM199511163332001.","journal-title":"N Engl J Med"},{"key":"1265_CR10","unstructured":"Administration USFaD: Pravachol HIGHLIGHTS OF PRESCRIBING INFORMATION. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019898s062lbl.pdf (2011). Accessed 09\u201317\u20132024 2024."},{"issue":"6A","key":"1265_CR11","doi-asserted-by":"publisher","first-page":"87S","DOI":"10.1016\/0002-9343(94)90238-0","volume":"96","author":"JD Banga","year":"1994","unstructured":"Banga JD, Jacotot B, Pfister P, Mehra M. Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study. French-Dutch Fluvastatin Study Group. Am J Med. 1994;96(6A):87S-93S. https:\/\/doi.org\/10.1016\/0002-9343(94)90238-0.","journal-title":"Am J Med."},{"issue":"21","key":"1265_CR12","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1001\/archinte.1994.00420210087010","volume":"154","author":"W Insull Jr","year":"1994","unstructured":"Insull W Jr, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, et al. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med. 1994;154(21):2449\u201355.","journal-title":"Arch Intern Med"},{"issue":"2","key":"1265_CR13","doi-asserted-by":"publisher","first-page":"41A","DOI":"10.1016\/s0002-9149(05)80015-3","volume":"76","author":"B Jacotot","year":"1995","unstructured":"Jacotot B, Banga JD, Waite R, Peters TK. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study Group. Am J Cardiol. 1995;76(2):41A-6A. https:\/\/doi.org\/10.1016\/s0002-9149(05)80015-3.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1265_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00019053-199814010-00006","volume":"14","author":"MJ Koren","year":"1998","unstructured":"Koren MJ, Smith DG, Hunninghake DB, Davidson MH, McKenney JM, Weiss SR, et al. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 1998;14(1):59\u201370. https:\/\/doi.org\/10.2165\/00019053-199814010-00006.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1265_CR15","doi-asserted-by":"publisher","first-page":"37A","DOI":"10.1016\/s0002-9149(05)80014-1","volume":"76","author":"JH Zavoral","year":"1995","unstructured":"Zavoral JH, Haggerty BJ, Winick AG, Bergmann SD. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor FLUENT Study Group Fluvastatin Long-Term Extension Trial. Am J Cardiol. 1995;76(2):37A-40A. https:\/\/doi.org\/10.1016\/s0002-9149(05)80014-1.","journal-title":"Am J Cardiol."},{"issue":"6A","key":"1265_CR16","doi-asserted-by":"publisher","first-page":"37S","DOI":"10.1016\/0002-9343(94)90230-5","volume":"96","author":"CA Dujovne","year":"1994","unstructured":"Dujovne CA, Davidson MH. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med. 1994;96(6A):37S-40S. https:\/\/doi.org\/10.1016\/0002-9343(94)90230-5.","journal-title":"Am J Med"},{"key":"1265_CR17","doi-asserted-by":"crossref","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383\u20139.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"issue":"5","key":"1265_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/s0149-2918(96)80045-2","volume":"18","author":"TM Heinonen","year":"1996","unstructured":"Heinonen TM, Stein E, Weiss SR, McKenney JM, Davidson M, Shurzinske L, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther. 1996;18(5):853\u201363. https:\/\/doi.org\/10.1016\/s0149-2918(96)80045-2.","journal-title":"Clin Ther"},{"issue":"5","key":"1265_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/01.atv.15.5.678","volume":"15","author":"JW Nawrocki","year":"1995","unstructured":"Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15(5):678\u201382. https:\/\/doi.org\/10.1161\/01.atv.15.5.678.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"1265_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/s0002-9149(03)00530-7","volume":"92","author":"PH Jones","year":"2003","unstructured":"Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152\u201360. https:\/\/doi.org\/10.1016\/s0002-9149(03)00530-7.","journal-title":"Am J Cardiol"},{"issue":"3","key":"1265_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2217\/clp.09.20","volume":"4","author":"D Budinski","year":"2009","unstructured":"Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clinical Lipidology. 2009;4(3):291\u2013302. https:\/\/doi.org\/10.2217\/clp.09.20.","journal-title":"Clinical Lipidology"},{"issue":"2","key":"1265_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.atherosclerosis.2008.02.008","volume":"201","author":"K Yokote","year":"2008","unstructured":"Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201(2):345\u201352. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.02.008.","journal-title":"Atherosclerosis"},{"issue":"11","key":"1265_CR23","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1185\/03007990903290886","volume":"25","author":"L Ose","year":"2009","unstructured":"Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin. 2009;25(11):2755\u201364. https:\/\/doi.org\/10.1185\/03007990903290886.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1265_CR24","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.clinthera.2014.06.009","volume":"36","author":"CA Sponseller","year":"2014","unstructured":"Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, Davidson MH. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014;36(8):1211\u201322. https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.009.","journal-title":"Clin Ther"},{"key":"1265_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ahj.2018.12.007","volume":"210","author":"HG Yebyo","year":"2019","unstructured":"Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18\u201328. https:\/\/doi.org\/10.1016\/j.ahj.2018.12.007.","journal-title":"Am Heart J"},{"issue":"20","key":"1265_CR26","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615\u201322. https:\/\/doi.org\/10.1001\/jama.279.20.1615.","journal-title":"JAMA"},{"key":"1265_CR27","unstructured":"Administration USFaD: Lescol HIGHLIGHTS OF PRESCRIBING INFORMATION. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020261s052,021192s026lbl.pdf (2005). Accessed September 19, 2024 2024."},{"key":"1265_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ijcard.2020.01.006","volume":"305","author":"M Moroi","year":"2020","unstructured":"Moroi M, Nagayama D, Hara F, Saiki A, Shimizu K, Takahashi M, et al. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol. 2020;305:139\u201346. https:\/\/doi.org\/10.1016\/j.ijcard.2020.01.006.","journal-title":"Int J Cardiol"},{"key":"1265_CR29","doi-asserted-by":"publisher","unstructured":"Heart Protection Study Collaborative G. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(02)09327-3.","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"1265_CR30","doi-asserted-by":"publisher","unstructured":"Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative G. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(03)13636-7.","DOI":"10.1016\/s0140-6736(03)13636-7"},{"issue":"9364","key":"1265_CR31","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(03)12948-0.","journal-title":"Lancet"},{"issue":"9435","key":"1265_CR32","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(04)16895-5.","journal-title":"Lancet"},{"issue":"4","key":"1265_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.7326\/M14-2820","volume":"162","author":"PM Ridker","year":"2015","unstructured":"Ridker PM, Cook NR. Comparing cardiovascular risk prediction scores. Ann Intern Med. 2015;162(4):313\u20134. https:\/\/doi.org\/10.7326\/M14-2820.","journal-title":"Ann Intern Med"},{"issue":"21","key":"1265_CR34","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa0807646.","journal-title":"N Engl J Med"},{"issue":"2","key":"1265_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/endocrines5020009","volume":"5","author":"RD Paparodis","year":"2024","unstructured":"Paparodis RD, Androulakis I, Askitis D, Perogamvros I, Angelopoulos N, Rizoulis A, et al. Secondary Cardiovascular Disease Prevention Deficit Persists over the Years: A Multicenter Cross-Sectional Study Involving 1003 Consecutive Patients from Greece. Endocrines. 2024;5(2):124\u201336.","journal-title":"Endocrines"},{"issue":"3","key":"1265_CR36","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1161\/01.cir.89.3.959","volume":"89","author":"D Waters","year":"1994","unstructured":"Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89(3):959\u201368. https:\/\/doi.org\/10.1161\/01.cir.89.3.959.","journal-title":"Circulation."},{"issue":"10","key":"1265_CR37","doi-asserted-by":"publisher","first-page":"969","DOI":"10.7326\/0003-4819-119-10-199311150-00002","volume":"119","author":"DH Blankenhorn","year":"1993","unstructured":"Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119(10):969\u201376. https:\/\/doi.org\/10.7326\/0003-4819-119-10-199311150-00002.","journal-title":"Ann Intern Med."},{"key":"1265_CR38","doi-asserted-by":"publisher","unstructured":"Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ. Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study. Ann N Y Acad Sci. 1995;748:407\u201317; discussion 17\u20138. https:\/\/doi.org\/10.1111\/j.1749-6632.1994.tb17337.x.","DOI":"10.1111\/j.1749-6632.1994.tb17337.x"},{"issue":"4","key":"1265_CR39","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1161\/01.cir.90.4.1679","volume":"90","author":"CD Furberg","year":"1994","unstructured":"Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90(4):1679\u201387. https:\/\/doi.org\/10.1161\/01.cir.90.4.1679.","journal-title":"Circulation."},{"issue":"10","key":"1265_CR40","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/hrt.2003.027284","volume":"90","author":"CH Lee","year":"2004","unstructured":"Lee CH, de Feyter P, Serruys PW, Saia F, Lemos PA, Goedhart D, et al. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS). Heart. 2004;90(10):1156\u201361. https:\/\/doi.org\/10.1136\/hrt.2003.027284.","journal-title":"Heart"},{"issue":"3","key":"1265_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/s0002-9149(97)00346-9","volume":"80","author":"JA Herd","year":"1997","unstructured":"Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ 3rd, Jones PH, West MS, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997;80(3):278\u201386. https:\/\/doi.org\/10.1016\/s0002-9149(97)00346-9.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1265_CR42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/euhj.1998.1150","volume":"20","author":"PW Serruys","year":"1999","unstructured":"Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J. 1999;20(1):58\u201369. https:\/\/doi.org\/10.1053\/euhj.1998.1150.","journal-title":"Eur Heart J"},{"issue":"1","key":"1265_CR43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1023\/B:CARD.0000025757.14093.e0","volume":"18","author":"CM Ballantyne","year":"2004","unstructured":"Ballantyne CM, Riegger G, Moore N, Saia F, Serruys PW. Fluvastatin reduces cardiac mortality in patients with coronary heart disease. Cardiovasc Drugs Ther. 2004;18(1):67\u201375. https:\/\/doi.org\/10.1023\/B:CARD.0000025757.14093.e0.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10","key":"1265_CR44","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/01.cir.91.10.2528","volume":"91","author":"JW Jukema","year":"1995","unstructured":"Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91(10):2528\u201340. https:\/\/doi.org\/10.1161\/01.cir.91.10.2528.","journal-title":"Circulation."},{"issue":"5","key":"1265_CR45","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/0735-1097(95)00301-0","volume":"26","author":"B Pitt","year":"1995","unstructured":"Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol. 1995;26(5):1133\u20139. https:\/\/doi.org\/10.1016\/0735-1097(95)00301-0.","journal-title":"J Am Coll Cardiol."},{"issue":"7","key":"1265_CR46","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1161\/01.cir.92.7.1758","volume":"92","author":"R Salonen","year":"1995","unstructured":"Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92(7):1758\u201364. https:\/\/doi.org\/10.1161\/01.cir.92.7.1758.","journal-title":"Circulation."},{"issue":"9","key":"1265_CR47","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1161\/01.cir.92.9.2419","volume":"92","author":"RP Byington","year":"1995","unstructured":"Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92(9):2419\u201325. https:\/\/doi.org\/10.1161\/01.cir.92.9.2419.","journal-title":"Circulation."},{"key":"1265_CR48","doi-asserted-by":"publisher","unstructured":"Long-Term Intervention with Pravastatin in Ischaemic Disease Study G. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349\u201357. https:\/\/doi.org\/10.1056\/NEJM199811053391902.","DOI":"10.1056\/NEJM199811053391902"},{"issue":"4","key":"1265_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jacc.2009.04.033","volume":"54","author":"T Hiro","year":"2009","unstructured":"Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009;54(4):293\u2013302. https:\/\/doi.org\/10.1016\/j.jacc.2009.04.033.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1265_CR50","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1253\/circj.cj-12-0135","volume":"76","author":"K Miyauchi","year":"2012","unstructured":"Miyauchi K, Daida H, Morimoto T, Hiro T, Kimura T, Nakagawa Y, et al. Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy\u2013the extended JAPAN-ACS study. Circ J. 2012;76(4):825\u201332. https:\/\/doi.org\/10.1253\/circj.cj-12-0135.","journal-title":"Circ J"},{"issue":"8923","key":"1265_CR51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(94)92082-6","volume":"344","author":"Effect of simvastatin on coronary atheroma","year":"1994","unstructured":"Effect of simvastatin on coronary atheroma. the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344(8923):633\u20138.","journal-title":"Lancet"},{"issue":"14","key":"1265_CR52","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425\u201335. https:\/\/doi.org\/10.1056\/NEJMoa050461.","journal-title":"N Engl J Med"},{"issue":"19","key":"1265_CR53","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437\u201345. https:\/\/doi.org\/10.1001\/jama.294.19.2437.","journal-title":"JAMA"},{"issue":"1","key":"1265_CR54","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ijcard.2012.01.078","volume":"157","author":"H Takagi","year":"2012","unstructured":"Takagi H, Umemoto T. Atorvastatin reduces coronary plaque volume in dependence on reductions in low-density lipoprotein: a meta-analysis and meta-regression of randomized controlled trials. Int J Cardiol. 2012;157(1):114\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2012.01.078.","journal-title":"Int J Cardiol"},{"issue":"7","key":"1265_CR55","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1253\/circj.CJ-18-1376","volume":"83","author":"Y Ozaki","year":"2019","unstructured":"Ozaki Y, Garcia-Garcia HM, Beyene SS, Hideo-Kajita A, Kuku KO, Kolm P, et al. Effect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaque on Optical Coherence Tomography - Review and Meta-Analysis. Circ J. 2019;83(7):1480\u20138. https:\/\/doi.org\/10.1253\/circj.CJ-18-1376.","journal-title":"Circ J"},{"issue":"10","key":"1265_CR56","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.amjcard.2015.08.010","volume":"116","author":"C Qian","year":"2015","unstructured":"Qian C, Wei B, Ding J, Wu H, Cai X, Li B, et al. Meta-analysis comparing the effects of rosuvastatin versus atorvastatin on regression of coronary atherosclerotic plaques. Am J Cardiol. 2015;116(10):1521\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2015.08.010.","journal-title":"Am J Cardiol"},{"issue":"12","key":"1265_CR57","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","volume":"297","author":"JR Crouse 3rd","year":"2007","unstructured":"Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O\u2019Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344\u201353. https:\/\/doi.org\/10.1001\/jama.297.12.1344.","journal-title":"JAMA"},{"issue":"13","key":"1265_CR58","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","volume":"295","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556\u201365. https:\/\/doi.org\/10.1001\/jama.295.13.jpc60002.","journal-title":"JAMA"},{"issue":"8","key":"1265_CR59","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/eurheartj\/ehu373","volume":"36","author":"L Raber","year":"2015","unstructured":"Raber L, Taniwaki M, Zaugg S, Kelbaek H, Roffi M, Holmvang L, et al. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Eur Heart J. 2015;36(8):490\u2013500. https:\/\/doi.org\/10.1093\/eurheartj\/ehu373.","journal-title":"Eur Heart J"},{"issue":"8 Pt 1","key":"1265_CR60","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.jcmg.2018.08.024","volume":"12","author":"L Raber","year":"2019","unstructured":"Raber L, Koskinas KC, Yamaji K, Taniwaki M, Roffi M, Holmvang L, et al. Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4): A Serial Optical Coherence Tomography Study. JACC Cardiovasc Imaging. 2019;12(8 Pt 1):1518\u201328. https:\/\/doi.org\/10.1016\/j.jcmg.2018.08.024.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"22","key":"1265_CR61","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","volume":"365","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078\u201387. https:\/\/doi.org\/10.1056\/NEJMoa1110874.","journal-title":"N Engl J Med"},{"issue":"13","key":"1265_CR62","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2021.15187","volume":"326","author":"J He","year":"2021","unstructured":"He J, Zhu Z, Bundy JD, Dorans KS, Chen J, Hamm LL. Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999\u20132018. JAMA. 2021;326(13):1286\u201398. https:\/\/doi.org\/10.1001\/jama.2021.15187.","journal-title":"JAMA"},{"issue":"10","key":"1265_CR63","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jacc.2014.06.1186","volume":"64","author":"KN Karmali","year":"2014","unstructured":"Karmali KN, Goff DC Jr, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC\/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64(10):959\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1186.","journal-title":"J Am Coll Cardiol"},{"key":"1265_CR64","doi-asserted-by":"publisher","unstructured":"Morris AA, Ko YA, Hutcheson SH, Quyyumi A. Race\/Ethnic and Sex Differences in the Association of Atherosclerotic Cardiovascular Disease Risk and Healthy Lifestyle Behaviors. J Am Heart Assoc. 2018;7(10). https:\/\/doi.org\/10.1161\/JAHA.117.008250.","DOI":"10.1161\/JAHA.117.008250"},{"key":"1265_CR65","doi-asserted-by":"publisher","unstructured":"Brown WV. Reaching goal: conquering the treatment gaps in dyslipidemia management. Clin Cardiol. 2003;26(4 Suppl 3):III1\u20132. https:\/\/doi.org\/10.1002\/clc.4960261502.","DOI":"10.1002\/clc.4960261502"},{"issue":"2","key":"1265_CR66","first-page":"78","volume":"95","author":"AR Last","year":"2017","unstructured":"Last AR, Ference JD, Menzel ER. Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults. Am Fam Physician. 2017;95(2):78\u201387.","journal-title":"Am Fam Physician"},{"issue":"25","key":"1265_CR67","doi-asserted-by":"publisher","first-page":"e1162","DOI":"10.1161\/CIR.0000000000000638","volume":"139","author":"DM Lloyd-Jones","year":"2019","unstructured":"Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC Jr, Sperling LS, Virani SS, et al. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. Circulation. 2019;139(25):e1162\u201377. https:\/\/doi.org\/10.1161\/CIR.0000000000000638.","journal-title":"Circulation"},{"key":"1265_CR68","doi-asserted-by":"publisher","first-page":"117272","DOI":"10.1016\/j.atherosclerosis.2023.117272","volume":"384","author":"C Antza","year":"2023","unstructured":"Antza C, Gallo A, Boutari C, Ershova A, Gurses KM, Lewek J, et al. Prevention of cardiovascular disease in young adults: Focus on gender differences. A collaborative review from the EAS Young Fellows. Atherosclerosis. 2023;384:117272. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117272.","journal-title":"Atherosclerosis."},{"issue":"6","key":"1265_CR69","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/MNH.0000000000000265","volume":"25","author":"K Matsushita","year":"2016","unstructured":"Matsushita K, Ballew SH, Coresh J. Cardiovascular risk prediction in people with chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25(6):518\u201323. https:\/\/doi.org\/10.1097\/MNH.0000000000000265.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"1265_CR70","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12967-021-03210-9","volume":"20","author":"WH Chang","year":"2022","unstructured":"Chang WH, Mueller SH, Chung SC, Foster GR, Lai AG. Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost. J Transl Med. 2022;20(1):2. https:\/\/doi.org\/10.1186\/s12967-021-03210-9.","journal-title":"J Transl Med"},{"issue":"3","key":"1265_CR71","doi-asserted-by":"publisher","first-page":"oeae032","DOI":"10.1093\/ehjopen\/oeae032","volume":"4","author":"J Lewek","year":"2024","unstructured":"Lewek J, Bielecka-Dabrowa A, Toth PP, Banach M. Dyslipidaemia management in pregnant patients: a 2024 update. Eur Heart J Open. 2024;4(3):oeae032. https:\/\/doi.org\/10.1093\/ehjopen\/oeae032.","journal-title":"Eur Heart J Open."},{"issue":"9","key":"1265_CR72","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40266-024-01139-4","volume":"41","author":"A Al-Ani","year":"2024","unstructured":"Al-Ani A, Jamil Y, Orkaby AR. Treating Hypercholesterolemia in Older Adults for Primary Prevention of Cardiovascular Events. Drugs Aging. 2024;41(9):699\u2013712. https:\/\/doi.org\/10.1007\/s40266-024-01139-4.","journal-title":"Drugs Aging"},{"issue":"9","key":"1265_CR73","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41569-021-00549-w","volume":"18","author":"JD Duarte","year":"2021","unstructured":"Duarte JD, Cavallari LH. Pharmacogenetics to guide cardiovascular drug therapy. Nat Rev Cardiol. 2021;18(9):649\u201365. https:\/\/doi.org\/10.1038\/s41569-021-00549-w.","journal-title":"Nat Rev Cardiol"},{"issue":"23","key":"1265_CR74","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","volume":"291","author":"DI Chasman","year":"2004","unstructured":"Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291(23):2821\u20137. https:\/\/doi.org\/10.1001\/jama.291.23.2821.","journal-title":"JAMA"},{"issue":"13","key":"1265_CR75","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/eurheartj\/ehs344","volume":"34","author":"JC Hopewell","year":"2013","unstructured":"Hopewell JC, Parish S, Offer A, Link E, Clarke R, Lathrop M, et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J. 2013;34(13):982\u201392. https:\/\/doi.org\/10.1093\/eurheartj\/ehs344.","journal-title":"Eur Heart J"},{"issue":"2","key":"1265_CR76","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","volume":"5","author":"DI Chasman","year":"2012","unstructured":"Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012;5(2):257\u201364. https:\/\/doi.org\/10.1161\/CIRCGENETICS.111.961144.","journal-title":"Circ Cardiovasc Genet"},{"issue":"9","key":"1265_CR77","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2217\/pgs-2018-0051","volume":"19","author":"T Zambrano","year":"2018","unstructured":"Zambrano T, Salazar LA. microRNAs and response to statins in patients with hypercholesterolemia: from basic research to precision medicine. Pharmacogenomics. 2018;19(9):748\u201351. https:\/\/doi.org\/10.2217\/pgs-2018-0051.","journal-title":"Pharmacogenomics"},{"issue":"3","key":"1265_CR78","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/ehjqcco\/qcab024","volume":"8","author":"HT May","year":"2022","unstructured":"May HT, Knowlton KU, Anderson JL, Lappe DL, Bair TL, Muhlestein JB. High-statin adherence over 5 years of follow-up is associated with improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease: results from the IMPRES study. Eur Heart J Qual Care Clin Outcomes. 2022;8(3):352\u201360. https:\/\/doi.org\/10.1093\/ehjqcco\/qcab024.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"3","key":"1265_CR79","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","volume":"4","author":"F Rodriguez","year":"2019","unstructured":"Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019;4(3):206\u201313. https:\/\/doi.org\/10.1001\/jamacardio.2018.4936.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"1265_CR80","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1161\/CIR.0000000000000677","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e563\u201395. https:\/\/doi.org\/10.1161\/CIR.0000000000000677.","journal-title":"Circulation"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01265-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-024-01265-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01265-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:45:43Z","timestamp":1758797143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-024-01265-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1007\/s11883-024-01265-9","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"6 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"No animal or human subjects by the authors were used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"21"}}